Bafisontamab

DB16091InvestigationalProtein Based Therapies

EMB-01 is under investigation in clinical trial NCT03797391 (A Dose Escalation Study of EMB-01 in Participants With Advanced/metastatic Solid Tumors).

Mechanism: Pharmacologically active on Epidermal growth factor receptor and Hepatocyte growth factor receptor
Curator reviewed
Also known as: Anti-egfr/anti-c-met bispecific antibody emb-01 · Anti-egfr/c-met bispecific antibody emb-01
Code names: EMB-01 · FIT-013a

Resolves to

Compound

UNIIG86X5QQ7M5

Targets

P00533EGFRP08581MET

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bafisontamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account